Lower incidence of vertebral fracture with romosozumab vs placebo for osteoporosis
Romosozumab Treatment in Postmenopausal Women with OsteoporosisN Engl J Med. 2016 Oct 20;375(16):1532-1543
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
7180 postmenopausal women with osteoporosis were randomized to 12 months of treatment with either romosozumab or placebo, followed by a further 12 months of treatment with denosumab in both groups. The purpose of this study was to evaluate and compare vertebral fracture incidence, nonovertebral fracture incidence, and safety outcomes between groups after 6, 12, 18, and 24 months. Results after 12 ...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE